2016
De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2012
Single Center Review of Seroconversion Rate and Clinical Outcomes of Kidney Transplant Recipients from Center for Disease Control (CDC) High Risk Donors
Bodner J, Katariya N, Hewitt W, Moss A, Mulligan D, Heilman R, Chakkera H, Hamawi K, Khamash H, Beck G, Reddy K. Single Center Review of Seroconversion Rate and Clinical Outcomes of Kidney Transplant Recipients from Center for Disease Control (CDC) High Risk Donors. Transplantation 2012, 94: 141. DOI: 10.1097/00007890-201211271-00260.Peer-Reviewed Original Research
2011
Impact of Acute Rejection on Kidney Allograft Outcomes in Recipients on Rapid Steroid Withdrawal
Heilman RL, Nijim S, Chakkera HA, Devarapalli Y, Moss AA, Mulligan DC, Mazur MJ, Hamawi K, Williams JW, Reddy KS. Impact of Acute Rejection on Kidney Allograft Outcomes in Recipients on Rapid Steroid Withdrawal. Journal Of Transplantation 2011, 2011: 583981. PMID: 21647349, PMCID: PMC3103882, DOI: 10.1155/2011/583981.Peer-Reviewed Original ResearchClinical acute rejectionRapid steroid withdrawalDeath-censored graft survivalKidney transplant recipientsSubclinical rejectionGraft survivalControl groupAcute rejectionSteroid withdrawalTransplant recipientsRejection groupCR groupDeceased donor kidney transplantInferior graft survivalMean HLA mismatchesKidney allograft outcomesDonor kidney transplantsAllograft outcomesAllograft survivalProtocol biopsiesHLA mismatchesBorderline changesKidney transplantPrimary outcomePersistent inflammation
2010
SUBCLINICAL ACUTE REJECTION IS ASSOCIATED WITH INFERIOR GRAFT SURVIVAL IN KIDNEY TRANSPLANT RECIPIENTS ON RAPID STEROID WITHDRAWAL
Heilman R, Davarapalli Y, Chakkera H, Mekeel K, Moss A, Williams J, Hamawi K, Mazur M, Mulligan D, Reddy K. SUBCLINICAL ACUTE REJECTION IS ASSOCIATED WITH INFERIOR GRAFT SURVIVAL IN KIDNEY TRANSPLANT RECIPIENTS ON RAPID STEROID WITHDRAWAL. Transplantation 2010, 90: 176. DOI: 10.1097/00007890-201007272-00341.Peer-Reviewed Original ResearchRelationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus
Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus. Clinical Journal Of The American Society Of Nephrology 2010, 5: 1669-1675. PMID: 20558559, PMCID: PMC2974410, DOI: 10.2215/cjn.09481209.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsInpatient hyperglycemiaKidney transplantationTransplant recipientsInsulin therapyNondiabetic kidney transplant recipientsDevelopment of NODATRisk of NODATNew-onset diabetesKidney transplant surgeryCapillary blood glucoseNondiabetic patientsYear posttransplantCardiovascular eventsNew onsetDiabetes mellitusMedical therapyAdjusted analysisStudy cohortRetrospective studyTransplant surgeryBlood glucoseSerum glucoseInsulin treatmentNODATImpact of Subclinical Inflammation on the Development of Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients
Heilman RL, Devarapalli Y, Chakkera HA, Mekeel KL, Moss AA, Mulligan DC, Mazur MJ, Hamawi K, Williams JW, Reddy KS. Impact of Subclinical Inflammation on the Development of Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients. American Journal Of Transplantation 2010, 10: 563-570. PMID: 20121731, DOI: 10.1111/j.1600-6143.2009.02966.x.Peer-Reviewed Original ResearchConceptsIF/TA scoreRapid steroid withdrawalSubclinical acute rejectionClinical acute rejectionSubclinical inflammationGroup 2Group 1Group 3Acute rejectionTubular atrophyInterstitial fibrosisGroup 4IF/TAProtocol biopsy findingsKidney transplant recipientsTA scoresProtocol biopsiesSteroid withdrawalTransplant recipientsBiopsy findingsInterstitial inflammationMore patientsMonths 1High riskPatients
2009
Pilot Study: Association of Traditional and Genetic Risk Factors and New-Onset Diabetes Mellitus Following Kidney Transplantation
Chakkera HA, Hanson RL, Raza SM, DiStefano JK, Millis MP, Heilman RL, Mulligan DC, Reddy KS, Mazur MJ, Hamawi K, Moss AA, Mekeel KL, Cerhan JR. Pilot Study: Association of Traditional and Genetic Risk Factors and New-Onset Diabetes Mellitus Following Kidney Transplantation. Transplantation Proceedings 2009, 41: 4172-4177. PMID: 20005362, PMCID: PMC3478878, DOI: 10.1016/j.transproceed.2009.08.063.Peer-Reviewed Original ResearchConceptsNew-onset diabetes mellitusDiabetes mellitusRisk factorsKidney transplantationTransplant recipientsFamily historyType 2 diabetes mellitusDevelopment of NODATKidney transplant recipientsTraditional risk factorsGenetic polymorphismsPositive family historyCommon risk factorsGenetic risk factorsLogistic regression modelsNODAT developmentNODAT riskPretransplant obesityNew onsetKidney transplantStudy cohortInsulin secretionNODATT2DMMellitusHyperglycemia during the Immediate Period after Kidney Transplantation
Chakkera HA, Weil EJ, Castro J, Heilman RL, Reddy KS, Mazur MJ, Hamawi K, Mulligan DC, Moss AA, Mekeel KL, Cosio FG, Cook CB. Hyperglycemia during the Immediate Period after Kidney Transplantation. Clinical Journal Of The American Society Of Nephrology 2009, 4: 853-859. PMID: 19339426, PMCID: PMC2666437, DOI: 10.2215/cjn.05471008.Peer-Reviewed Original ResearchConceptsNew-onset diabetesKidney transplantationPretransplantation diabetesHospital dischargeImmediate posttransplantation periodPrevalence of hypoglycemiaKidney transplant recipientsStress of surgeryShort-acting insulinEvidence of hyperglycemiaHospital stayImmunosuppression medicationsPharmacologic managementTransplant recipientsHospital phasePosttransplantation periodPharmacy databaseStudy cohortProspective studyTransient hyperglycemiaObservational studyMetabolic effectsHyperglycemiaPatientsTransplantationUse of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Clinical Transplants 2009, 407-14. PMID: 20524306.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmBoronic AcidsBortezomibCreatinineFemaleGraft RejectionHLA AntigensHumansImmunoglobulins, IntravenousImmunosuppressive AgentsIsoantibodiesKidney TransplantationMaleMiddle AgedProtease InhibitorsPyrazinesRituximabTreatment OutcomeConceptsKidney transplant recipientsUse of bortezomibTransplant recipientsCase reportBortezomibRecipientsOutcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2008
RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY
Moss A, Heilman R, Chakkera H, Mazur M, Petrides S, Wosniak E, Mekeel K, Mulligan D, Reddy K. RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY. Transplantation 2008, 86: 591-592. DOI: 10.1097/01.tp.0000330970.94094.7a.Peer-Reviewed Original Research
2007
Clinical factors associated with graft fibrosis in kidney‐transplant recipients on steroid‐avoidance immunosuppression
Heilman RL, Chakkera HA, Reddy KS, Colby TV, Moss AA, Williams JW, Mazur MJ, Petrides S, Mulligan DC. Clinical factors associated with graft fibrosis in kidney‐transplant recipients on steroid‐avoidance immunosuppression. Clinical Transplantation 2007, 22: 309-315. PMID: 18482051, DOI: 10.1111/j.1399-0012.2007.00786.x.Peer-Reviewed Original ResearchConceptsSteroid avoidance immunosuppressionKidney-pancreas transplant recipientsOne-year biopsyKidney transplant recipientsBK nephropathySerum creatinineProtocol biopsiesRecipient ageTransplant recipientsGraft fibrosisUnadjusted logistic regression analysisLower body mass indexMultivariate logistic regression modelCI scoresPrimary kidney transplantsPancreas transplant recipientsBody mass indexInterstitial cellular infiltrateLogistic regression analysisLogistic regression modelsAcute rejectionAntigen mismatchesAntithymocyte globulinGraft outcomeKidney transplant
2006
THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY.
Moss A, Heilman R, Mazur M, Chakkera H, Wozniak E, Post D, Mulligan D, Reddy K. THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY. Transplantation 2006, 82: 292. DOI: 10.1097/00007890-200607152-00679.Peer-Reviewed Original ResearchAnti-thymocyte globulin induction therapyLow-dose intravenous immunoglobulinDose intravenous immunoglobulinFlow cytometry crossmatchDonor-specific antibodiesKidney transplant recipientsCytometry crossmatchInduction therapyIntravenous immunoglobulinTransplant recipientsCrossmatchTherapyImmunoglobulinRecipientsAntibodiesCLINICAL VARIABLES ASSOCIATED WITH GRAFT FIBROSIS (GF) ON 12 MONTH PROTOCOL BIOPSY IN KIDNEY TRANSPLANT RECIPIENTS ON STEROID AVOIDANCE IMMUNOSUPPRESSION (SA).
Heilman R, Reddy K, Chakkera H, Mazur M, Moss A, Williams J, Colby T, Petrides S, Mulligan D. CLINICAL VARIABLES ASSOCIATED WITH GRAFT FIBROSIS (GF) ON 12 MONTH PROTOCOL BIOPSY IN KIDNEY TRANSPLANT RECIPIENTS ON STEROID AVOIDANCE IMMUNOSUPPRESSION (SA). Transplantation 2006, 82: 461-462. DOI: 10.1097/00007890-200607152-01187.Peer-Reviewed Original ResearchRESOURCE UTILIZATION IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B CELL, FLOW B AND/OR T CELL CROSS MATCH TREATED WITH LOW DOSE IVIG AND THYMOGLOBULIN® INDUCTION THERAPY.
Post D, Moss A, Mulligan D, Heilman R, Mazur M, Chakkera H, Reddy K. RESOURCE UTILIZATION IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B CELL, FLOW B AND/OR T CELL CROSS MATCH TREATED WITH LOW DOSE IVIG AND THYMOGLOBULIN® INDUCTION THERAPY. Transplantation 2006, 82: 668. DOI: 10.1097/00007890-200607152-01815.Peer-Reviewed Original ResearchLow-dose IVIGKidney transplant recipientsInduction therapyTransplant recipientsCross matchB cellsIVIGThymoglobulinTherapyRecipientsAcute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk
2005
Steroid Avoidance Immunosuppression in Low-Risk Kidney Transplant Recipients
Heilman R, Mazur M, Reddy K, Moss A, Post D, Mulligan D. Steroid Avoidance Immunosuppression in Low-Risk Kidney Transplant Recipients. Transplantation Proceedings 2005, 37: 1785-1788. PMID: 15919466, DOI: 10.1016/j.transproceed.2005.02.106.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsLow-risk kidney transplant recipientsChronic allograft nephropathyPostoperative day 3Steroid avoidanceTransplant recipientsLow-immunologic risk kidney transplant recipientsDay 3Anti-thymocyte globulin inductionRabbit anti-thymocyte globulinRisk kidney transplant recipientsIncidence of PTDMPositive flow crossmatchSteroid avoidance immunosuppressionTrough tacrolimus levelsAnti-thymocyte globulinGraft survival ratesSerum creatinine levelsShort-term safetyRecent clinical trialsDay of transplantationActuarial patientAcute rejectionAllograft nephropathyGlobulin induction